Bloomberg: “Slaoui sits on the boards of several companies involved in the vaccine chase, presenting a potential conflict of interest...As a board member in 2019, Slaoui earned $490,000 from Moderna”
“‘I’m the same venture capitalist you talked to last week,’ he told POLITICO on Monday”
Washington, DC – Today, Patients Over Pharma released the following statement on reports that former head of GlaxoSmithKline’s vaccine division Moncef Slaoui will serve as the Trump administration’s “therapeutics czar.”
“Former pharma executive Moncef Slaoui would feel right at home in a Trump Administration filled with drug company allies and friends,” said Eli Zupnick, spokesman for Patients Over Pharma. “What patients need right now is someone in this Administration willing to take on the drug companies and make sure every American can access and afford COVID-19 vaccines, not another drug company executive.”
Additional reporting from Bloomberg: “Slaoui…joined the board of Lonza Group AG, a Swiss medical company that has contracted with Moderna to manufacture its vaccine. He’s also on the board of SutroVax Inc., a closely held vaccine developer. As a board member in 2019, Slaoui earned $490,000 from Moderna, including $65,000 in cash and $425,000 in options awards, according to a corporate filing….He’s a partner at the venture capital firm Medicxi.”
Earlier this year, Patients Over Pharma released an updated and expanded version of their BigPharmasBestFriends.org website, which reveals the latest on Trump Administration officials who made millions of dollars from the pharmaceutical industry, the number of pharmaceutical companies and lobbying groups represented in the Trump administration, the revolving door between the Trump Administration and the pharmaceutical industry, and more.